𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer; A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age

✍ Scribed by Carsten Rose; Claus Kamby; Henning T. Mouridsen; Michael Andersson; Lars Bastholt; Knud Aage Møller; Jørn Andersen; Pia Munkholm; Per Dombernowsky; Ib Jarle Christensen

Book ID
110235684
Publisher
Springer US
Year
2000
Tongue
English
Weight
58 KB
Volume
61
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized trial of tamoxifen alone or
A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma
✍ James N. Ingle; Vera J. Suman; Carl G. Kardinal; James E. Krook; James A. Mailli 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 2 views

## BACKGROUND. Tamoxifen (TAM) is generally considered the hormonal agent of choice for postmenopausal women with hormone receptor positive breast carcinoma. The somatostatin analogues, including octreotide, have demonstrated inhibition of breast carcinoma cell lines and multiple endocrinologic act